On-demand PrEP efficacy: forgiveness or timely dosing.,The Lancet HIV

当前位置： X-MOL 学术 › Lancet HIV › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

On-demand PrEP efficacy: forgiveness or timely dosing.
The Lancet HIV ( IF 12.8 ) Pub Date : 2019-11-26 , DOI: 10.1016/s2352-3018(19)30332-7
Jean-Jacques Parienti ₁

Affiliation

Oral daily pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate plus emtricitabine can be highly protective against HIV infection. However, its effectiveness is dependent on drug intake. In large randomised placebo-controlled trials, ^, objective measures of adherence have closely predicted the extent of protection against HIV in the intention-to-treat population ( ). The proxy for adherence was the percentage of patients for whom tenofovir was detected in plasma in all studies, with the exception of the PROUD study that used the percentage of days covered by PrEP over 2 years of follow-up.

中文翻译：

按需PrEP功效：宽恕或及时给药。

含有替诺福韦富马酸替诺福韦酯和恩曲他滨的口服每日暴露前预防（PrEP）对HIV感染具有高度保护作用。但是，其有效性取决于药物的摄入量。在大型的随机安慰剂对照试验，^，坚持客观的措施，紧紧预测抗HIV保护的意向性治疗人群的程度（）。依从性的替代指标是在所有研究中血浆中检出替诺福韦的患者百分比，但PROUD研究除外，该研究使用了PrEP在2年的随访期内所占的天数百分比。

更新日期：2020-02-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文